WHO ICTRP trial
The efficacy of evolocumab on thin-fiber cap plaque in patients with very…
ChiCTR2000032570 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000032570 |
|---|---|
| Public title | The efficacy of evolocumab on thin-fiber cap plaque in patients with very high-risk ASCVD: a randomized controlled trial |
| Scientific title | The efficacy of evolocumab on thin-fiber cap plaque in patients with very high-risk ASCVD: a randomized controlled trial |
| Primary sponsor | Chinese Cardiovascular Association- Access Fund |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Cardiovascular disease |
| Interventions | experimental group:Atorvastatin 40mg/day combined with evolocumab 140mg subcutaneous injection once every 2 weeks;control group:Atorvastatin 40mg/day |
| Registration date | May 2, 2020 |
| Target size | experimental group:12;control group:12 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: